Screw DMOAD. IMO it is a rabbit hole that, if it remains our focus, will just continue to delay registration.
Significant pain reduction and functional improvement with such small sample sizes is OUTSTANDING news.
I'm loving the focus in the headline on pain (rather than DMOAD). I'm also loving the focus on a specific dose. They are signalling clarity regarding approach to FDA, which is very welcome.
Well done to them.
Ann: iPPS SIGNIFICANT OA PAIN REDUCTION AT 12 MONTHS, page-15
-
- There are more pages in this discussion • 223 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |